Strides Shasun is currently trading at Rs. 1121.55, up by 36.10 points or 3.33% from its previous closing of Rs. 1085.45 on the BSE.
The scrip opened at Rs. 1098.00 and has touched a high and low of Rs. 1132.00 and Rs. 1090.10 respectively. So far 31,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1412.45 on 23-Nov-2015 and a 52 week low of Rs. 822.20 on 10-Feb-2015.
Last one week high and low of the scrip stood at Rs. 1132.00 and Rs. 964.00 respectively. The current market cap of the company is Rs. 10,025.00 crore.
The promoters holding in the company stood at 27.65% while Institutions and Non-Institutions held 44.42% and 27.94% respectively.
Strides Shasun has received order on January 21, 2016 under the Competition Act, 2002 from the Competition Commission of India (CCI) approving the proposed transaction of the company for acquisition of Ranbaxy’s two CNS divisions. With this approval, all necessary regulatory approvals have been obtained.
Last year in September, the company was in process of acquiring Ranbaxy’s two divisions in Central Nervous System (CNS) segment in India from Sun Pharmaceutical Industries for Rs 165 crore. The pharma major and Sun Pharma had entered into a definitive agreement related to erstwhile Ranbaxy’s ‘Solus’ and ‘Solus Care’ divisions.
Strides Shasun (formerly known as Strides Arcolab) is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: